S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
OTCMKTS:CNBX

CNBX Pharmaceuticals News Headlines

$9.69
+0.69 (+7.67%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.10
$9.70
50-Day Range
$6.76
$10.56
52-Week Range
$0.06
$0.23
Volume
1,766 shs
Average Volume
106,408 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get CNBX Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

CNBX Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CNBX
News Sentiment

0.50

0.46

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CNBX Articles
This Week

2

0

CNBX Articles
Average Week



CNBX Pharmaceuticals (OTCMKTS:CNBX) News Headlines Today

SourceHeadline
barrons.com logoCNBX Pharmaceuticals Inc.
barrons.com - May 14 at 9:19 PM
seekingalpha.com logoCNBX pharma granted patent in Hong Kong for cancer therapy
seekingalpha.com - May 5 at 2:39 PM
finance.yahoo.com logoCNBX Pharmaceuticals Granted Patent in Hong Kong
finance.yahoo.com - May 5 at 9:26 AM
msn.com logoNovartis to save at least $1 billion by 2024 thanks to simplified structure
msn.com - April 4 at 6:24 PM
msn.com logoVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killer
msn.com - April 4 at 6:24 PM
cnbc.com logoWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stake
cnbc.com - April 4 at 9:20 AM
msn.com logoStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and more
msn.com - April 4 at 9:20 AM
cnbc.com logoCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit Today
cnbc.com - April 1 at 4:04 PM
cnbc.com logoWhat to watch today: Wall Street set to wrap up strong month but weak quarter
cnbc.com - April 1 at 4:04 PM
msn.com logoStocks making the biggest moves premarket: Walgreens, Baidu, Novavax and others
msn.com - April 1 at 4:04 PM
msn.com logoVertex Pharmaceuticals reports positive data on non-opioid pain medicine
msn.com - April 1 at 4:04 PM
finance.yahoo.com logoCannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
finance.yahoo.com - March 28 at 6:44 PM
benzinga.com logoAvicanna To Bring Its Cannabinoid-Based Drugs To Argentina Via 'Established' Pharma Partner
benzinga.com - November 30 at 6:44 PM
finance.yahoo.com logoCNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
finance.yahoo.com - November 4 at 12:40 PM
finance.yahoo.com logoMeet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago
finance.yahoo.com - October 26 at 2:02 PM
finance.yahoo.com logoRadiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors
finance.yahoo.com - October 25 at 12:42 PM
finance.yahoo.com logoCEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
finance.yahoo.com - October 19 at 2:31 PM
finance.yahoo.com logoCannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
finance.yahoo.com - October 18 at 1:24 PM
finance.yahoo.com logoCEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference
finance.yahoo.com - October 14 at 9:25 AM
finance.yahoo.com logoCannabics Announces New Corporate Logo, New Website and New Company Presentation
finance.yahoo.com - September 30 at 11:05 AM
finance.yahoo.com logoGabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
finance.yahoo.com - September 22 at 12:26 PM
finance.yahoo.com logoCannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
finance.yahoo.com - September 21 at 10:57 AM
finance.yahoo.com logoNeuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
finance.yahoo.com - September 13 at 9:15 AM
finance.yahoo.com logoHemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors
finance.yahoo.com - August 23 at 3:44 PM
benzinga.com logoJ&J's Janssen Denied Data Protection Rights For Ketamine Analog Spravato In Canada, Court Rules 'Not An Innovative Drug'
benzinga.com - August 10 at 10:54 PM
finance.yahoo.com logoWorld-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
finance.yahoo.com - August 4 at 8:45 AM
benzinga.com logoClever Leaves And Biopharma Research Co. Will Study DNA Sequencing Of Cannabis Under 'Project Change Lives' Initiative
benzinga.com - July 28 at 7:18 PM
benzinga.com logoNew Cannabis Products: A Professional Cosmetic Line, A CBD Sports Recovery Line And Marine Collage
benzinga.com - July 23 at 11:58 PM
benzinga.com logoWill Psychedelics Continue To Grow In 2021? Fund Managers Share Insights And Strategies As More Companies Go Public
benzinga.com - July 23 at 6:58 PM
seekingalpha.com logoCannabics names Inbar Maymon-Pomeranchik as independent board director
seekingalpha.com - July 9 at 3:17 PM
finance.yahoo.com logoCannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
finance.yahoo.com - June 28 at 9:26 AM
markets.businessinsider.com logoCannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
markets.businessinsider.com - June 17 at 8:22 AM
finance.yahoo.com logoCannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
finance.yahoo.com - June 3 at 9:33 AM
finance.yahoo.com logoThe European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
finance.yahoo.com - May 25 at 11:13 AM
finance.yahoo.com logoCannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
finance.yahoo.com - May 11 at 9:52 AM
finance.yahoo.com logoCannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)
finance.yahoo.com - May 6 at 12:53 PM
benzinga.com logoUSDA Teams Up With Illinois-Based Chemical Producer To Create Hemp-Based 'Cosmeceuticals'
benzinga.com - May 1 at 9:27 AM
finance.yahoo.com logoCannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track
finance.yahoo.com - April 26 at 1:16 PM
finance.yahoo.com logoCannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
finance.yahoo.com - April 20 at 2:01 PM
finance.yahoo.com logoCannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
finance.yahoo.com - March 31 at 2:19 PM
seekingalpha.com logoCannabics' RCC-33 prolongs survival rate in mice inoculated with human colorectal cancer cells
seekingalpha.com - March 19 at 12:48 PM
finance.yahoo.com logoCannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
finance.yahoo.com - March 17 at 10:18 AM
benzinga.com logoVoyager Makes Dosing Simple, Safe And Precise To Optimize The Cannabis Experience Through Cannabis Drops
benzinga.com - March 11 at 8:53 AM
benzinga.com logoGaard Labs Launches Several Lines Of CBD Products In The Big Apple
benzinga.com - February 25 at 7:04 PM
finance.yahoo.com logoCannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
finance.yahoo.com - February 17 at 1:40 PM
finance.yahoo.com logoCannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
finance.yahoo.com - February 16 at 2:22 PM
finance.yahoo.com logoCannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
finance.yahoo.com - February 3 at 9:48 AM
benzinga.com logoKlay Thompson, Alex Morgan, Travis Pastrana, Paul Rodriguez Talk About Their New CBD Brand
benzinga.com - February 2 at 11:28 PM
benzinga.com logoHow Will Psychedelics Become Medicine? A Scientific Review Of The Drug Development Pathway
benzinga.com - January 3 at 10:53 PM
markets.businessinsider.com logoNews for Cannabics Pharmaceuticals
markets.businessinsider.com - December 24 at 7:52 AM
Get CNBX Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.